On203: The Anti-Oxmif Antibody Targeting Solid Tumors

ON203: the anti-oxMIF antibody targeting solid tumors

The rationale behind the MIF-targeting antibody ON203 for solid tumors

New Frontiers in Immuno-oncology for Solid Tumor Treatment

Alliance for Regenerative Medicine

The macrophage migration inhibitory factor (MIF) as a therapeutic and diagnostic target

Dr. Cohen on mTOR Inhibition in Head and Neck Cancer

Tumour immunology and immunotherapy

Targeting macrophages for solid tumor immunotherapy

Research Square

Targeting Tumor Associated Macrophages in Ovarian Cancer

The Antibody Society

Sym015: MET antibody mixture for advanced solid tumors

The Impact of the Tumor Microenvironment

Charles River Labs

Phase I trial of IMA401, a MAGEA4/8-directed T cell receptor bispecific in solid tumors

DS-7300 demonstrates durable antitumor activity in advanced solid tumors

Immune Checkpoint Inhibitors, The Next Generation Cancer Therapy - Creative Biolabs

Creative Biolabs

Cancer Research UK explains how immune cells could tackle tumours

Combinatorial Immunotherapy Approaches for Patients with Advanced Solid Tumors

Immune suppression and dysfunction in lymphoma tumors

VJHemOnc – Video Journal of Hematology & HemOnc

New Cellular Target May Inhibit Deadly Brain Tumor

Cleveland Clinic

Phase I/II trial of GV20-0251, a novel checkpoint inhibitor, in solid tumors

What are Immune Checkpoints?

Promega Corporation

Anti-tumor immunity in the lymphoid microenvironment

VJHemOnc – Video Journal of Hematology & HemOnc